Initial characteristics and clinical outcome
| Characteristic . | RAS* (n = 44) . | Non-RAS (n = 123) . |
|---|---|---|
| Age, y | ||
| Median (Range) | 42 (4-81) | 35 (1-76) |
| >55 | 11 (25%) | 21 (17%) |
| Gender | ||
| Male | 23 (52%) | 57 (46%) |
| Performance status | ||
| 0 | 17 (39%) | 54 (43%) |
| 1 | 17 (39%) | 51 (41%) |
| >1 | 10 (22%) | 18 (16%) |
| White blood cell count at diagnosis (per μL) | ||
| Median (Range) | 1450 (400-35 900) | 2000 (300-64 800) |
| >10 000 | 3 (7%) | 20 (17%) |
| M3v | 2 (4%) | 21 (17%) |
| PML-RARα | ||
| BCR1 (L) | 16 (59%) | 43 (53%) |
| BCR2 (V) | 0 | 7 (9%) |
| BCR3 (S) | 10 (37%) | 27 (33%) |
| True negative | 1 (4%) | 4 (5%) |
| Hydroxyurea at entry | 3 (4%) | 19 (15%) |
| Outcome | ||
| Complete response | 28 (64%) | 93 (76%) |
| 3-y disease-free survival | 74% | 66% |
| Characteristic . | RAS* (n = 44) . | Non-RAS (n = 123) . |
|---|---|---|
| Age, y | ||
| Median (Range) | 42 (4-81) | 35 (1-76) |
| >55 | 11 (25%) | 21 (17%) |
| Gender | ||
| Male | 23 (52%) | 57 (46%) |
| Performance status | ||
| 0 | 17 (39%) | 54 (43%) |
| 1 | 17 (39%) | 51 (41%) |
| >1 | 10 (22%) | 18 (16%) |
| White blood cell count at diagnosis (per μL) | ||
| Median (Range) | 1450 (400-35 900) | 2000 (300-64 800) |
| >10 000 | 3 (7%) | 20 (17%) |
| M3v | 2 (4%) | 21 (17%) |
| PML-RARα | ||
| BCR1 (L) | 16 (59%) | 43 (53%) |
| BCR2 (V) | 0 | 7 (9%) |
| BCR3 (S) | 10 (37%) | 27 (33%) |
| True negative | 1 (4%) | 4 (5%) |
| Hydroxyurea at entry | 3 (4%) | 19 (15%) |
| Outcome | ||
| Complete response | 28 (64%) | 93 (76%) |
| 3-y disease-free survival | 74% | 66% |
RAS indicates the retinoic acid syndrome; BCR, breakpoint cluster region; L, long form; V, variable form; S, short form.